Stockreport

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2 [Yahoo! Finance]

Arvinas, Inc.  (ARVN) 
Last arvinas, inc. earnings: 11/4 05:00 pm Check Earnings Report
PDF – Preclinical data presented at the Biennial International LRRK2 Meeting highlighted the promise of PROTAC ® -induced leucine-rich repeat kinase 2 (LRRK2) degradation a [Read more]